论文部分内容阅读
目的:探讨合贝爽联合辛伐他汀治疗颈动脉粥样硬化患者的C-反应蛋白(CRP)及斑块(AP)的临床疗效。方法:回顾性分析我院2008年1月至2009年9月因短暂性脑缺血发作且确诊为颈动脉粥样硬化的患者132例,随机分为4组:常规治疗组、合贝爽治疗组、辛伐他汀治疗组与合贝爽联用辛伐他汀治疗组,每组患者33例,持续用药治疗15周,分析比较4组患者治疗前后颈动脉内中膜厚度(IMT)和AP面积,血脂和CRP水平,观察治疗期间各组患者脑血管事件的发生情况。结果:持续用药治疗15周后,所有患者的CRP、LDL-C、TC与TG的水平明显降低,HDL-C的水平显著升高,差异均有统计学意义,P<0.05。与其它3组的治疗效果相比,合贝爽联合辛伐他汀治疗组的疗效最佳,该组患者血脂各指标的变化除TC外,其它4个指标与其它三组的差异均有统计学意义,P<0.05;该组的颈动脉内中膜厚度变得更薄,颈动脉粥样硬化斑块面积变得更小,P<0.01。结论:合贝爽联合辛伐他汀可使颈动脉粥样硬化患者的颈动脉内膜厚度变薄、斑块面积缩小,改善血液微环境。
Objective: To investigate the clinical efficacy of Hiabang combined with simvastatin in treating C-reactive protein (CRP) and plaque (AP) in patients with carotid atherosclerosis. Methods: A retrospective analysis of our hospital from January 2008 to September 2009 due to transient ischemic attack and diagnosed as carotid atherosclerosis in 132 patients, were randomly divided into 4 groups: conventional treatment group, combined with Pui Shuang treatment Group, Simvastatin group and Hebai Shuang combined with simvastatin group, 33 patients in each group were treated for 15 weeks. The IMT and AP area of the four groups were compared before and after treatment , Blood lipids and CRP levels were observed in each group during treatment of cerebrovascular events. Results: The levels of CRP, LDL-C, TC and TG in all patients were significantly decreased and the levels of HDL-C were significantly increased in all patients after 15 weeks of treatment. The difference was statistically significant, P <0.05. Compared with the other three groups, the combination of simvastatin and simvastatin had the best curative effect. The changes of the indexes of blood lipid in this group were statistically different from the other three groups except TC Significance, P <0.05; carotid intima-media thickness in this group became thinner, carotid atherosclerotic plaque area became smaller, P <0.01. CONCLUSION: Combine with simvastatin can attenuate carotid intima-media thickness in patients with carotid atherosclerosis, reduce plaque area and improve blood microenvironment.